¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"response rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • myotatic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ, Çö󼼺¸¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ìµå·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response
    ¹ÝÀÀ
  • response bias
    ¹ÝÀÀÄ¡¿ìħ
  • response curve
    ¹ÝÀÀ°î¼±
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • response modulation
    ¹ÝÀÀÁ¶Á¤
  • response prevention
    ¹ÝÀÀ¿¹¹æ
  • reticulocyte response
    ±×¹°ÀûÇ÷±¸¹ÝÀÀ, ¸Á»óÀûÇ÷±¸¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • glomerular filtration rate
    Å丮¿©°úÀ², »ç±¸Ã¼¿©°úÀ²
  • heart rate
    ½ÉÀå¹Úµ¿¼ö
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü
  • morbidity rate
    ÀÌȯ·ü
  • mortality rate
    »ç¸Á·ü
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • onset rate
    ¹ß»ý·ü
  • operative mortality rate
    ¼ö¼ú»ç¸Á·ü
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • perfusion rate
    °ü·ù¼Óµµ, °ü·ùÀ²
  • pregnancy rate
    Àӽŷü
  • prevalence rate
    À¯º´·ü
  • pulse rate
    ¸Æ¹Ú¼ö
  • relaxation rate
    À̿Ϸü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦
  • inert response
    ºÒȰ¼º¹ÝÀÀ
  • inflammatory response
    ¿°Áõ¹ÝÀÀ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£
  • inverse response
    ¿ª¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • myotactic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • response modulation
    ¹ÝÀÀÁ¶Á¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • positive placebo response
    Çö󼼺¸Ä¡·á È¿°ú.
  • pressure response
    À½¾Ð¹ÝÀÀ(ëåäâÚãëë).
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • radiation response
    ¹æ»ç¼±¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ(ÔÑê¬Úãëë).
  • BMR=£¾basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • GFR => glomerular filtration rate
    »ç±¸Ã¼¿©°úÀ²
  • GFR= glomerular filtration rate
    »ç±¸Ã¼(ÞêϹô÷)°Å¸§·ü(×È).
  • GFR= glomerular filtration rate
    »ç±¸Ã¼°Å¸§·ü.
  • Heart rate
    ½É¹Ú¼ö(ãýÚÑâ¦)
  • MVR=£¾maximus voiding rate
    ÃÖ´ë¹è´¢À².
  • Westergren sedimentation rate
    ¿þ½ºÅͱ׷»Ä§°­¼Óµµ
  • absorbed dose rate
    Èí¼ö¼±·®À²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • conditioned emotional response
    Á¶°ÇÈ­°¨Á¤¹ÝÀÀ(ðÉËìûùÊïï×Úãëë)
  • conditioned fear response
    Á¶°ÇÈ­°øÆ÷¹ÝÀÀ(ðÉËìûùÍðø×Úãëë)
  • conditioned response
    Á¶°ÇÈ­¹ÝÀÀ(ðÉËìûùÚãëë)
  • consummatory response
    ¼ºÃë¹ÝÀÀ(à÷ö¦Úãëë)
  • delayed response
    Áö¿¬¹ÝÀÀ(òÀæÅÚãëë).
  • dose response curve
    ¹æ»ç [¾à¸®,º´¸®,»ýÈ­,ÇÙÀÇ]¿ë·®¹ÝÀÀ°î¼±(éÄåÖÚãëëÍØàÊ).
  • dose response curve
    ¹æ»ç ¾à¸®,º´¸®,»ýÈ­,ÇÙÀǿ뷮´ëÀÀ°î¼±(éÄåÖÓßëëÍØàÊ).
  • dose response curve/relationship
    ¿ë·®-¹ÝÀÀ°î¼±/°ü°è.
  • dose response relationship
    ¹æ»ç ¾à¸®,»ý¸®,»ýÈ­,ÇÙÀǿ뷮¹ÝÀÀ°ü°è (¡­Î¼Ìõ).
  • dose-response curve
    ¼±·®¹ÝÀÀ°î¼±
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±(éÄÕáÚãëëÍØàÊ)
  • dose-response relationship
    ¼±·®¹ÝÀÀ°ü°è
  • double response
    ÀÌÁß¹ÝÀÀ(¡­Úãëë).
  • emotional response
    °¨Á¤¹ÝÀÀ.
  • evoked response
    À¯¹ß¹ÝÀÀ(ë¯Û¡Úãëë).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • phosphatidylinositol response
    Æ÷½ºÆÄƼµô ´ëÀÀ(Óßëë)
  • PI response
    PI ´ëÀÀ(Óßëë)
  • pleiotypic response
    ´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
  • primary immune response
    ÀÏÂ÷ ¸é¿ª´ëÀÀ(ìéó­Øóæ¹Óßëë)
  • primary response
    ÀÏÂ÷ ´ëÀÀ(ìéó­Óßëë)
  • SOS response
    SOS ´ëÀÀ(Óßëë)
  • staircase response
    °è´Ü ´ëÀÀ(Í­Ó«Óßëë)
  • stringent response
    ¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
  • tertiary response
    »ïÂ÷´ëÀÀ (ß²ó­Óßëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IR drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat...
WR Wassermann reaction; water retention; weakly reactive; weak response; whole response; wiping reactio...
HR heart rate; hemorrhagic retinopathy; high resolution; higher rate; histamine receptor; hormonal resp...
ACR abnormally contracting region; absolute catabolic rate; acriflavine; adenomatosis of colon and rectu...
MR Maddox rods; magnetic resistance; magnetic resonance; mandibular reflex; mannose-resistant; may repe...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AR Attack Rate
ADMR Average daily metabolic rate
BMR Basal Metabolic Rate
BFR Blood flow rate
BFR Bone formation rate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sensitization response
    °¨ÀÛ ¹ÝÀÀ
  • stimulus response assessment
    ÀÚ±Ø ¹ÝÀÀ Æò°¡
  • thermal camera time response
    ¿­ Ä«¸Þ¶ó ½Ã°£ ¹ÝÀÀ
  • unconditioned response
    ¹«Á¶°Ç ¹ÝÀÀ
  • wide dynamic range response characteristics
    ±¤µ¿¹üÀ§ ¹ÝÀÀ Ư¡, ±¤µ¿Àû ¹üÀ§ ¹ÝÀÀ Ư¡
  • absorptace rate
    Èí¼öÀ²
    ÀÎü¿¡ Á¶»çµÇ´Â ¹æ»ç¼±¿¡ ´ëÇØ ÀÎü¿¡ Èí¼öµÇ´Â ¹æ»ç¼± ¿¡³ÊÁöÀÇ ºñÀ².
  • absorption rate
    Èí¼öÀ²
    ÀÏÁ¤ ½Ã°£¿¡ »¡¾ÆµéÀÌ´Â ¼Óµµ¸¦ ³ªÅ¸³»´Â À².
  • adjusted death rate
    Á¶Á¤ »ç¸Á·ü
  • attack rate
    ¹ßº´·ü, ÀÌȯÀ²
  • basal metabolic rate
    ±âÃÊ ´ë»çÀ²
    ½Ä»ç ÈÄ ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª°í ³ª¼­ÀÇ ¾ÈÁ¤ »óÅ¿¡¼­ÀÇ »ê¼Ò ¼Òºñ ¼Óµµ.
  • cardiac rate
    ½É¹Ú ¼ö
    µ¿ÀǾî=heart rate.
  • caries incidence rate
    ¿ì½Ä¹ß»ýÀ²
    ÀÏÁ¤ÇÑ ±â°£¿¡ ¹ß»ýÇÏ´Â ¿ì½Ä ¹ß»ýÀ², ¨ç Æò±Õ ³â°£ ¿ì½Ä¹ß»ýÀ² =
  • case fatality rate
    Ä¡¸í·ü
  • conversion rate
    ÀüȯÀ²
  • D.E.F. rate
    µð.ÀÌ.¿¡ÇÁ
    Decayed Extractlion, FilledÀÇ ¾àÀÚ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
humoral immune response <immunology> Those immune responses mediated by antibody.
(06 Mar 1998)
serum response element Dyad symmetry element bound by serum response factor to control the expression of c fos.
(18 Nov 1997)
serum response factor Transcription factor that binds to the serum response element upstream of the site of transcription initiation of genes such as c fos.
(18 Nov 1997)
signal response coupling The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
hypersensitive response An active response of plant cells to pathogenic attack in which the cell undergoes rapid necrosis and dies. Associated with the production of phytoalexins, lignin and sometimes callose. The response is thought to prevent a potential pathogen from spreading through the tissues.
(18 Nov 1997)
sonomotor response Widespread myogenic potential evoked by click stimulation.
(05 Mar 2000)
sos response (genetics) An error-prone mechanism or set of functions for repairing damaged microbial DNA. Sos functions (a concept reputedly derived from the sos of the international distress signal) are involved in DNA repair and mutagenesis, in cell division inhibition, in recovery of normal physiological conditions after DNA repair, and possibly in cell death when DNA damage is extensive.
(12 Dec 1998)
stringent response The cellular response to amino acid starvation that reduces the amount of ribosomes to what can be employed under the nutrient conditions.
(05 Mar 2000)
depletion response Subnormal metabolic response to trauma in a person whose physiologic processes are already depressed by disease.
(05 Mar 2000)
dose-response curve This is a graph to show the relation between the dose of a drug or other chemical and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(09 Oct 1997)
dose-response relationship Relationship in which a change in the amount, intensity, or duration of exposure is associated with a change in risk of a specified outcome.
(05 Mar 2000)
dose-response relationship, drug The relationship between the dose of an administered drug and the response of the organism to the drug.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
immune response <immunology> Alteration in the reactivity of an organisms immune system in response to an antigen, in vertebrates, this may involve antibody production, induction of cell-mediated immunity, complement activation or development of immunological tolerance.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • discount rate
    ¾îÀ½ ÇÒÀÎÀ²;ÀçÇÒÀÎÀ²
  • economic growth rate
    °æÁ¦ ¼ºÀå·ü 9
  • effective exchange rate
    (±ÝÀ¶)½ÇÈ¿ ȯ½Ã¼¼(ȯÀ²)(±¹Á¦ÅëÈ­±â±ÝÀÌ ´çÇØ±¹°ú ´Ù¸¥ ÁÖ¿ä 20°³±¹ ÅëÈ­ÀÇ È¯½Ã¼¼¸¦ º¹ÇÕ½ÃÄÑ »êÃâÇÏ´Â Áö¼ö)
  • exchange rate
    ȯÀ²
  • fatality rate
    »ç¸Á·ü
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • flat rate
    °íÁ¤(Á¤¾×)¿ä±Ý
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • floating rate
    ÀÚÀ¯ º¯µ¿ ½Ã¼¼;¼±Çϼ¼
  • forward rate
    (¿Ü±¹È¯ÀÇ) ¼±¹° ½Ã¼¼
  • freight rate
    ¿îÀÓ·ü Àå
  • fuel rate
    Ãʰ£ ¿¬·á ¼ÒºñÀ²
  • interest rate
    ±Ý¸®ÀÌÀ²
  • kill rate
    (ÀüÀï,Æøµ¿ µîÀÇ)»ì»ý·ü 9
  • milline rate
    1milline ´çÀÇ ±¤°í·á
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á